title: P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use.
abstract: Dual antiplatelet therapy (DAPT), which includes the combination of aspirin and a P2Y12 platelet receptor inhibitor, is a well-established antiplatelet regimen in the treatment of patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Three P2Y12 inhibitor options (clopidogrel, prasugrel and ticagrelor) are currently available, all having different efficacy and safety profiles along with contrasting contraindications, special warnings and precautions for use. This review compares and contrasts the unique P2Y12 antagonists in the NSTE-ACS setting, covering the latest evidence and their optimal use.
authors.affiliation: University at Buffalo School of Pharmacy & Pharmaceutical Sciences, NYS Center of Excellence, Bioinformatics & Life Sciences, 701 Ellicott St, B3-322, Buffalo, NY 14203, USA.
authors.forename: Nicholas B
authors.initials: NB
authors.lastname: Norgard
authors.affiliation: Department of Preventive Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.
authors.forename: James J
authors.initials: JJ
authors.lastname: DiNicolantonio
keywords: P2Y12 antagonists; acute coronary syndrome; clopidogrel; prasugrel; ticagrelor